TYK2 and systemic lupus erythematosus: Emerging data suggest that TYK2 inhibition, exemplified by deucravacitinib, may offer a mechanistically appealing approach in selected patients by modulating both IL-23-mediated Th17 activity and type I interferon signaling, with supportive evidence from Phase II SLE studies, CLE transcriptomic analyses, and early real-world overlap reports [35,36,37].